<i>NO control: nitric oxide directly regulates substrate delivery to NOS.</i> Focus on “Nitric oxide can acutely modulate its biosynthesis through a negative feedback mechanism on <scp>l</scp>-arginine transport in cardiac myocytes”

Gatto, Craig

doi:10.1152/ajpcell.00191.2010

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study observed significant decreases in BP parameters (SBP, DBP) after the 8-week intervention. Similar findings were reported in previous studies ( 13 , 26 ). L-arginine supplementation was found to be associated with significant decreases in SBP and DBP in patients with essential hypertension ( 13 ).…”

Section: Discussionsupporting

confidence: 93%

“…Similar findings were reported in previous studies ( 13 , 26 ). L-arginine supplementation was found to be associated with significant decreases in SBP and DBP in patients with essential hypertension ( 13 ). A possible partial association has been suggested between impaired L-arginine transport and the risk of hypertension development, possibly indicating an association between defective L-arginine/NO pathway signaling and the onset of hypertension ( 27 ).…”

Section: Discussionsupporting

confidence: 93%

“…Numerous studies have demonstrated the effective use of L-arginine for the prevention of many diseases associated with endothelium dysfunction, such as atherosclerosis and diabetes ( 13 - 15 ). Piatti et al reported that L-arginine treatment significantly improved peripheral and hepatic insulin sensitivity in patients with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

et al. 2016

View full text Add to dashboard Cite

Background:Recently, the potential of L-arginine supplementation as a novel and effective strategy for weight loss and improving biochemical parameters in obese patients has been under consideration.Objectives:To evaluate the influence of 8-week oral L-arginine supplementation on body mass index (BMI), waist circumference (WC), triceps skinfold (TS), subscapular skinfold (SS), systolic blood pressure (SBP), diastolic blood pressure (DBP), plasma fasting blood sugar (FBS), glycated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and malondialdehyde (MDA) in patients with BMI values > 29.9 or visceral obesity (WC > 102 cm in men or > 88 cm in women).Patients and Methods:Ninety obese patients were included in a single-blind randomized controlled trial. Patients were randomized to receive either L-arginine (3 or 6 g thrice daily) or placebo for 8 weeks. Anthropometric and biochemical indices, dietary intake, and blood pressure values were measured at the baseline and after the 8-week intervention.Results:Significant decreases in anthropometric parameters, blood pressure (SBP, DBP), FBS, HbA1c, LDL, MDA (P < 0.001), TG (P = 0.02), and TC (P = 0.002) and a significant increase in HDL (P < 0.001) were observed in the intervention group, compared to the control group. In the control group, no significant differences were found between the baseline and end-of-intervention measurements.Conclusions:In conclusion, oral L-Arginine supplementation appears to improve anthropometric parameters, blood pressure values, and some blood biochemical indices associated with cardiovascular disease prevention.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated the effective use of L-arginine for the prevention of many diseases associated with endothelium dysfunction, such as atherosclerosis and diabetes (13)(14)(15). Piatti et al reported that L-arginine treatment significantly improved peripheral and hepatic insulin sensitivity in patients with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

Mazloom

Dashtabi

Fararouei³

et al. 2016

Res Cardiovasc Med

View full text Add to dashboard Cite

Background:Recently, the potential of L-arginine supplementation as a novel and effective strategy for weight loss and improving biochemical parameters in obese patients has been under consideration. Objectives: To evaluate the influence of 8-week oral L-arginine supplementation on body mass index (BMI), waist circumference (WC), triceps skinfold (TS), subscapular skinfold (SS), systolic blood pressure (SBP), diastolic blood pressure (DBP), plasma fasting blood sugar (FBS), glycated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and malondialdehyde (MDA) in patients with BMI values > 29.9 or visceral obesity (WC > 102 cm in men or > 88 cm in women). Patients and Methods: Ninety obese patients were included in a single-blind randomized controlled trial. Patients were randomized to receive either L-arginine (3 or 6 g thrice daily) or placebo for 8 weeks. Anthropometric and biochemical indices, dietary intake, and blood pressure values were measured at the baseline and after the 8-week intervention. Results: Significant decreases in anthropometric parameters, blood pressure (SBP, DBP), FBS, HbA1c, LDL, MDA (P < 0.001), TG (P = 0.02), and TC (P = 0.002) and a significant increase in HDL (P < 0.001) were observed in the intervention group, compared to the control group. In the control group, no significant differences were found between the baseline and end-of-intervention measurements. Conclusions:In conclusion, oral L-Arginine supplementation appears to improve anthropometric parameters, blood pressure values, and some blood biochemical indices associated with cardiovascular disease prevention.

show abstract

Effects of L-arginine supplementation on biomarkers of glycemic control: a systematic review and meta‐analysis of randomised clinical trials

Karimi

Hatami

Ghavami

et al. 2021

Archives of Physiology and Biochemistry

View full text Add to dashboard Cite

NO control: nitric oxide directly regulates substrate delivery to NOS. Focus on “Nitric oxide can acutely modulate its biosynthesis through a negative feedback mechanism on l-arginine transport in cardiac myocytes”

Cited by 3 publications

References 29 publications

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo controlled clinical trial

Effects of L-arginine supplementation on biomarkers of glycemic control: a systematic review and meta‐analysis of randomised clinical trials

Contact Info

Product

Resources

About